Alto Neuroscience, Inc. (NYSE:ANRO) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Alto Neuroscience, Inc. (NYSE:ANRO) has been given a consensus rating of “Moderate Buy” by the ten research firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $35.25.

A number of brokerages recently weighed in on ANRO. JonesTrading dropped their price objective on Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating on the stock in a research report on Thursday, April 2nd. Weiss Ratings raised Alto Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 1st. Jefferies Financial Group reaffirmed a “buy” rating and set a $35.00 price objective on shares of Alto Neuroscience in a research report on Monday, March 16th. BTIG Research raised their price objective on Alto Neuroscience from $27.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th. Finally, Wedbush raised their price objective on Alto Neuroscience from $21.00 to $24.00 and gave the company a “neutral” rating in a research report on Thursday, May 14th.

Institutional Investors Weigh In On Alto Neuroscience

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Perceptive Advisors LLC raised its stake in Alto Neuroscience by 12.6% in the first quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company’s stock valued at $45,182,000 after buying an additional 225,500 shares during the last quarter. Bank of America Corp DE raised its stake in Alto Neuroscience by 131.5% in the first quarter. Bank of America Corp DE now owns 25,677 shares of the company’s stock valued at $577,000 after buying an additional 14,585 shares during the last quarter. Eversept Partners LP purchased a new stake in Alto Neuroscience in the first quarter valued at about $2,814,000. The Manufacturers Life Insurance Company purchased a new stake in Alto Neuroscience in the first quarter valued at about $534,000. Finally, Quantinno Capital Management LP raised its stake in Alto Neuroscience by 1.4% in the first quarter. Quantinno Capital Management LP now owns 36,069 shares of the company’s stock valued at $811,000 after buying an additional 490 shares during the last quarter.

Alto Neuroscience Price Performance

Shares of ANRO stock opened at $21.57 on Friday. Alto Neuroscience has a 1-year low of $2.15 and a 1-year high of $28.44. The stock’s 50-day moving average is $22.71 and its 200 day moving average is $19.51. The company has a market cap of $756.72 million, a P/E ratio of -8.91 and a beta of 1.22. The company has a debt-to-equity ratio of 0.07, a current ratio of 20.52 and a quick ratio of 20.52.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.24). Research analysts predict that Alto Neuroscience will post -3.01 earnings per share for the current fiscal year.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.